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ABSTRACT: There are currently no eﬀective therapies for
ﬁbrodysplasia ossiﬁcans progressiva (FOP), a debilitating and
progressive heterotopic ossiﬁcation disease caused by activat-
ing mutations of ACVR1 encoding the BMP type I receptor
kinase ALK2. Recently, a subset of these same mutations of
ACVR1 have been identiﬁed in diﬀuse intrinsic pontine glioma
(DIPG) tumors. Here we describe the structure−activity
relationship for a series of novel ALK2 inhibitors based on the
2-aminopyridine compound K02288. Several modiﬁcations
increased potency in kinase, thermal shift, or cell-based assays
of BMP signaling and transcription, as well as selectivity for
ALK2 versus closely related BMP and TGF-β type I receptor
kinases. Compounds in this series exhibited a wide range of in vitro cytotoxicity that was not correlated with potency or
selectivity, suggesting mechanisms independent of BMP or TGF-β inhibition. The study also highlights a potent 2-
methylpyridine derivative 10 (LDN-214117) with a high degree of selectivity for ALK2 and low cytotoxicity that could provide a
template for preclinical development. Contrary to the notion that activating mutations of ALK2 might alter inhibitor eﬃcacy due
to potential conformational changes in the ATP-binding site, the compounds demonstrated consistent binding to a panel of
mutant and wild-type ALK2 proteins. Thus, BMP inhibitors identiﬁed via activity against wild-type ALK2 signaling are likely to
be of clinical relevance for the diverse ALK2 mutant proteins associated with FOP and DIPG.
■ INTRODUCTION
Bone morphogenetic proteins (BMPs) are members of the
transforming growth factor-beta (TGF-β) signaling family,
which includes over 30 diﬀerent ligands.1 BMP signaling is
essential for numerous processes, including cell fate determi-
nation, embryonic patterning, and iron homeostasis.2,3 The
BMP signaling cascade parallels that of TGF-β signaling. BMP
ligand dimers bind to transmembrane receptor complexes
consisting of two constitutively active type II receptor kinases
(BMPRII, ACTRIIA, or ACTRIIB), which transphosphorylate
and activate two type I receptor kinases (ALK1, ALK2, ALK3,
or ALK6).4 Activated type I receptors phosphorylate eﬀector
proteins (SMAD1/5/8) that complex with SMAD4, translocate
to the nucleus, and activate BMP responsive genes such as the
inhibitor of diﬀerentiation (Id) gene family. Functional and
anatomic speciﬁcity of BMP signaling is regulated by the
spatiotemporal expression of ligands and their cognate
receptors as well as the expression of endogenous BMP
antagonists such as noggin.5,6
Inappropriate BMP signaling has been shown to contribute
to the pathophysiology of various disease processes.7 One of
the most striking examples of BMP signaling-related disease is
seen in ﬁbrodysplasia ossiﬁcans progressiva (FOP), a rare and
disabling genetic disease aﬀecting approximately 2500 people
worldwide.8 While individuals with the classical form of FOP
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are nearly normal at birth except for cervical and hallux joint
deformities, during early life they develop progressive formation
of endochondral bone in muscles, fascia, and ligaments, leading
to severe immobility, pain, and premature mortality. A highly
conserved gain-of-function mutation in the glycine−serine
(GS) rich domain of the BMP type-I receptor ALK2
(c.617G>A; p.R206H) accounts for more than 98% of cases
of classic FOP.9,10 Several other FOP-causing gain-of-function
mutations in both the GS and kinase domains of ALK2 have
also been described in nonclassic or variant forms of FOP.10−14
Recently, several of the mutations identiﬁed in classic and
nonclassic forms of FOP have been observed to arise in a
proportion of tumors in diﬀuse intrinsic pontine glioma, a
deadly childhood tumor also without eﬀective therapies.15−18
The consistency of this ﬁnding across diverse patient cohorts by
several independent groups suggests an important role of
somatic activating mutations of ACVR1 in this disease,
however, the pathogenetic role of these mutant proteins is
currently under investigation.
We and others have previously reported the discovery and
development of small molecule inhibitors of BMP type-I
receptors such as dorsomorphin, LDN-193189, LDN-212854,
and DMH1, all of which are based on the pyrazolo[1,5-
a]pyrimidine scaﬀold (Figure 1).19−21 These compounds have
proven to be useful chemical reagents for the study of in vitro
phenomenon, and several have demonstrated in vivo eﬃcacy in
a mouse model of FOP.21,22 More recently we described a
structurally distinct BMP type-I receptor inhibitor, K02288,
which is based on a 2-aminopyridine scaﬀold and demonstrated
greater kinome-wide selectivity than LDN-193189.23 The 2-
aminopyridine scaﬀold is also found in crizotinib, which was
recently approved by the FDA for the treatment of nonsmall
cell lung cancer in patients with activating mutations in the
anaplastic lymphoma kinase.24 Despite the high aﬃnity and
selectivity of K02288 for BMP receptors in thermal shift and in
vitro kinase assays, it has comparatively weak potency in cell-
based assays.21
In this article, we describe a structure−activity relationship
(SAR) study of K02288 with respect to ALK2 binding aﬃnity,
BMP and TGF-β signaling inhibition in biochemical and
cellular assays, selectivity, and cytotoxicity. These studies were
pursued as part of an eﬀort to elucidate the BMP type I
receptor inhibitor pharmacophore, while producing a set of
compounds with greater utility as physiologic probes. This SAR
provides unique insights into features of 2-aminopyridine
derivatives that are required for potent and selective inhibition
of ALK2 versus closely related BMP and TGF-β receptors. We
found that substitution of the 3-phenol with 4-phenylpiperazine
greatly increased potency in cells, yielding a series of
compounds more likely to be useful as probes of ALK2
function. These included a 2-methylpyridine derivative that
exhibited potent and relatively selective inhibition of ALK2
activity in cell-based and in vitro kinase assays, high selectivity
across the kinome, and low cytotoxicity. Additionally, we used
this novel set of derivatives to demonstrate for the ﬁrst time
that FOP-causing mutations do not aﬀect inhibitor binding
aﬃnity as compared to wild-type ALK2. This ﬁnding strongly
suggests that ATP-competitive kinase inhibitors identiﬁed on
the basis of their activity against endogenous BMP signaling,
such as dorsomorphin and its derivatives, or by their aﬃnity for
wild-type ALK2, as in the case of K02288, will inhibit with
equal potency the mutant ALK2R206H found in classical FOP as
well as the other GS- and kinase-domain mutants of ALK2 that
have been described in nonclassical or variant FOP or DIPG.
These results describe a novel series of speciﬁc and potent
probe compounds for the interrogation of BMP signaling that
may have therapeutic potential for FOP and other diseases of
maladaptive or inappropriate BMP signaling.
■ RESULTS AND DISCUSSION
Chemistry. A series of 2-amino-3-(3,4,5-trimethoxyphenyl)-
pyridine derivatives were synthesized according to the
procedures outlined in Scheme 1. Commercially available 2-
amino-5-bromo-3-iodopyridine (1) was coupled with 3,4,5-
trimethoxyphenylboronic acid under Suzuki reaction conditions
to give 2 in 80% yield.25−27 This intermediate was subjected to
a second Suzuki reaction with a range of boronic acids to
furnish the target compounds 3 in 40−85% yield.
A variety of 2-substituted 3-aryl-5-(piperazinylphenyl)-
pyridine derivatives were synthesized according to the method
outlined in Scheme 2. An aryl group was ﬁrst introduced at the
3-position of pyridine 1 or 4 via a Suzuki coupling to provide 5
in 65−85% yield. This was followed by a second Suzuki
reaction using [(N-Boc)piperazin-1-yl]phenylboronic acid
pinacol esters to generate 6, which was deprotected using
triﬂuoroacetic acid (TFA) in dichloromethane at room
temperature to give amines 7. Starting material 4 (R =
NHMe or NMe2) was prepared by reductive amination of 1 in
Figure 1. Previously described BMP inhibitors.
Scheme 1. General Procedure for the Synthesis of 2-Amino-
3-(3,4,5-trimethoxyphenyl)pyridine Derivativesa
aReagents and conditions: (a) 3,4,5-trimethoxyphenylboronic acid,
MeCN/DMF, Na2CO3 (aqueous, 1 M), 10 mol % Pd(PPh3)4, 90 °C,
8 h, 80%; (b) arylboronic acid, DME, Na2CO3 (aqueous, 1 M), 10 mol
%, Pd(PPh3)4, 90 °C, 8 h, 40−85%.
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dichloromethane using various amounts of paraformaldehyde in
the presence of NaBH(OAc)3.
3-Aryl-5-(4-piperazinylphenyl)pyridine derivatives containing
a methyl substituent in the 2-position of the pyridine were
prepared using the method outlined in Scheme 3. The 2-
chloropyridine 8 was treated with trimethylboroxine in the
presence of a palladium catalyst to generate 2-methylpyridine 9
in 90% yield.28 The carbamate protecting group was again
removed with TFA to generate 10.
On the basis of several physiochemical properties, including
calculated octanol−water partition coeﬃcient (cLogP), dis-
tribution coeﬃcient (cLogD7.4), topological polar surface area
(tPSA in Å2), and number of hydrogen bond donors, acceptors
(HBD and HBA) and rotatable bonds (Supporting Informa-
tion, Table 1), the prepared compounds are predicted to be cell
permeable and orally absorbed.29,30
SAR of Solvent Exposed Position. We previously demon-
strated that K02288 exhibits similar potency to LDN-193189 in
biochemical kinase assays for inhibiting ALK2 and related BMP
type I receptor kinases but was surprisingly less active in cell-
based reporter assays using constitutively active BMP type I
receptors.21,23 We speculated the relatively weaker activity of
K02288 in cells might be due to poor solubility or impaired
interactions with solvent water molecules that might be
addressed via modiﬁcations in the solvent-exposed domain.
We created six derivatives of K02288 by modifying the 3-
phenol substituent, which in the co-crystal structure of ALK2
occupied the solvent-exposed hydrophobic channel at the
entrance of the ATP pocket (Supporting Information, Figure
1). Here, several functional groups were used as replacements
of the 3-phenol (Figure 2a,b), chosen either to mimic hydrogen
bonding of the phenol with Asp293 or to introduce an
electropositive charge (e.g., a protonated amine) to mediate an
ionic interaction with Asp293, thus maintaining a potentially
important interaction. To gain insight into the potency and
selectivity for BMP vs TGF-β signaling, derivatives were tested
for their ability to bind BMP type I receptor ALK2 and TGF-β
type I receptor ALK5, using an in vitro thermal shift kinase
assay (Figure 2c). This type of assay has been previously shown
by us and others to be highly predictive of biochemical kinase
inhibition activity,31 which was also measured in a selected
subset of the derivatives (Figures 2−5). Tm shift data were
found to correlate highly (r2 ≥ 0.8) with biochemical inhibition
data (Supporting Information, Figure 2). To assess the potency
and selectivity of these compounds in cells, inhibition of BMP6-
induced transcriptional activity (BRE-Luciferase) and TGF-β1-
induced transcriptional activity (CAGA-Luciferase) was meas-
ured for each of the compounds (Figure 2c), using cell lines
(C2C12 for BMP6 and HEK293T for TGF-β1) previously
shown to express a complement of BMP or TGF-β receptors
required for ligand-mediated signaling.32 In general, the
magnitude of ΔTm for ALK2 and ALK5 correlated inversely
with the log IC50 for inhibition of BMP and TGF-β-induced
transcriptional activity (Figure 1d) but with some minor
exceptions. Notably, K02288 exhibited a large thermal shift for
ALK2 kinase protein (ΔTm = 13.2 °C), consistent with potent
inhibition of ALK2 activity by biochemical assay (IC50 = 34
nM) but was substantially weaker in the cell-based assay of
BMP6 activity (IC50 = 421 nM, Figure 2c). Of the variants at
the 3-phenol position, compound 13 exhibited the best in vitro
inhibition of ALK2, whereas compound 15 demonstrated the
best cell-based activity. The occasional discordance between
biochemical (ΔTm and enzymatic) and functional assays
(ligand-induced transcription) highlighted the need for multiple
assays in an SAR aimed at identifying physiologic probes with
useful potency and selectivity.
In addition to altering potency, modiﬁcations to the solvent-
exposed 3-phenol showed signiﬁcant alterations in selectivity.
Replacing 3-phenol with 4-phenol (11) increased potency
against BMP6 signaling by ∼20-fold compared to K02288
while retaining a modest degree of selectivity for BMP6 versus
TGF-β1 signaling (28-fold, Figure 2c). Adding a 3-methoxy
group to the 4-phenol (12) reduced BMP6 inhibition modestly,
with similar selectivity. Replacing the 3-phenol with a
bioisosteric methylsulfonamide (13) improved BMP6 inhib-
ition compared to K02288 but decreased selectivity. The
largest increase in potency occurred with the replacement of
the 3-phenol with 3- or 4-phenylpiperazine, as previously done
with LDN-193189, likely due to the increased polarity of this
Scheme 2. General Procedure for the Synthesis of Various 2-
Substituted 3-Aryl-5-(piperazinylphenyl)pyridine
Derivativesa
aReagents and conditions: (a) arylboronic acid, MeCN/DMF,
Na2CO3 (aqueous, 1 M), 10 mol % Pd(PPh3)4, 90 °C, 8 h, 65−
85%; (b) [(N-Boc)piperazin-1-yl]phenylboronic acid pinacol ester,
DME, Na2CO3 (aqueous, 1 M), 10 mol % Pd(PPh3)4, 90 °C, 8 h, 70−
75%; (c) TFA, DCM, rt, 12 h, 100%.
Scheme 3. Synthesis of a 2-Methyl 3-Aryl-5-(4-piperazinylphenyl)pyridine Derivativesa
aReagents and conditions: (a) trimethylboroxine, 1,4-dioxane, K2CO3 (2 equiv), 20 mol % Pd(PPh3)4, 110 °C, 8 h, 90%; (b) TFA, DCM, rt, 12 h,
100%.
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substituent resulting in both improved inhibitor aqueous
solubility and increased enthalpic interactions with solvent
water molecules.19 Compounds 14 and 15 demonstrated 70−
100-fold increases in BMP6 inhibition (IC50 = 6 nM, and 4
nM) compared to K02288, with modest improvements in
selectivity. Compound 15 is structurally similar to previously
disclosed aminopyridine inhibitors of interleukin-2-inducible T-
cell kinase (ITK) and pyridine benzamide inhibitors of protein
kinase D (PKD).33,34 To further investigate the type I receptor
selectivity of 15, cells were transfected with adenoviruses
expressing constitutively active BMP type I receptors (caALK1,
caALK2, and caALK3) and constitutively active activin or TGF-
β type I receptors (caALK4 and caALK5) in low serum
conditions and in the absence of exogenous ligand (Supporting
Information, Figure 3). Derivative 15 was most potent against
BMP receptors caALK2 and caALK3 with IC50 measurements
of ∼3.5 nM, whereas the activin/TGF-β type I receptors and
caALK1 were inhibited with with an IC50 measurements of ∼20
nM, with nearly complete extinction of BMP and TGF-β type I
receptor signaling at approximately 250 nM. Taken together,
these data demonstrate that replacing the 3-phenol in the
solvent exposed region of K02288 with 4-phenylpiperazine
dramatically improved its potency in cells but with relatively
poor selectivity for BMP versus TGF-β signaling. These results
prompted us to explore structural variants at other positions
that might reﬁne selectivity while retaining gains in potency
aﬀorded by modiﬁcation of the solvent-exposed 3-phenol with
4-phenylpiperazine in 15.
SAR of Hydrophobic Pocket Position. Further modiﬁcations
of potent compound 15 were performed to develop an SAR for
the 3,4,5-trimethoxyphenyl group (R2) (Figure 3a,b) to identify
the role of each methoxy group on potency and selectivity. The
trimethoxyphenyl group has previously been shown to interact
with the hydrophobic back pocket in ALK2 where it forms
water-mediated hydrogen bonds with the catalytic lysine
residue (K235) (Supporting Information, Figure 1). Com-
pounds were again proﬁled in thermal shift, biochemical
enzyme inhibition, and cell-based luciferase reporter assays
(Figure 3b,c).
Removal of any of the methoxy groups resulted in a
signiﬁcant decrease in BMP inhibition. However, particular
methoxy groups were more crucial than others. For example,
removing one of the 3-methoxy groups (16) resulted in a 35-
fold loss in potency compared to 15, although selectivity for
BMP6 inhibition versus TGF-β increased. Removing the 4-
methoxy group (17) decreased activity 10-fold but did not
improve selectivity. Combining these changes (18) demon-
strated that the 4-methoxy group contributed less signiﬁcantly
to BMP6 inhibition as compared to either meta-methoxy group.
As expected, removal of both meta-methoxy groups, while
Figure 2. Potency and selectivity of K02288 derivatives based on thermal shift, biochemical kinase activity, and ligand induced transcriptional activity
assays. (a) The 2-aminopyridine scaﬀold of K02288. (b) Modiﬁcations to the solvent exposed domain (R1) of K02288. (c) Thermal shift (ΔTm),
biochemical enzymatic inhibition (IC50) for ALK2 and ALK5 kinase proteins, and inhibition of cell-based BMP6 and TGF-β1-induced
transcriptional activity (IC50) by K02288 derivative compounds (nd = not determined). (d) Correlation of thermal shift and cell-based BMP/TGF-β
inhibition assays.
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retaining the para-methoxy group (20) drastically reduced
potency by almost 500-fold. Incorporating the 3,4-dimethoxy
groups into a benzo-1,4-dioxane (19) resulted in decreased
activity compared to 16, perhaps reﬂecting disruption of the
hydrogen bond with ALK2 residue K235. In addition,
increasing the steric bulk of the 3-alkoxy group (21) or
replacing the 4-methoxy with a chlorine (22) or a methyl (23)
were also not productive. In conclusion, of the compounds
studied the 3,4,5-trimethoxphenyl group resulted in the best
balance between BMP6 inhibition and selectivity over TGF-β.
This is likely due to its greater molecular volume for occupying
the hydrophobic pocket in ALK2 while retaining hydrogen
bond acceptors in the meta-positions of the phenyl ring. Future
studies will seek to optimize binding in the hydrophobic pocket
by replacing the 3,4,5-trimethoxyphenyl entirely with a diverse
set of aryl and heteroaryl moieties.
SAR of Hinge Binding Position. To further explore the SAR
of 15, we modiﬁed the primary amine residue of the 2-
aminopyridine (R3, Figure 4a,b), a region that was previously
shown to interact with the hinge region of the ALK2 kinase
domain. Here, the amine was within hydrogen bonding
distance to the backbone carbonyl of H284, as well as the
gatekeeper residue T283 of ALK2 (Supporting Information,
Figure 1). Both residues are changed in ALK5 (D281 and S280,
respectively). Secondary and tertiary amines such as 24 and 25,
respectively, exhibited reduced potency in both the thermal
shift and cell-based assays. Similarly, 28, in which the primary
amine is replaced with a methoxy substituent, exhibited
decreased potency, suggesting that bulky substituents are not
well tolerated at this position. Notably, these compounds
exhibited negligible thermal shift despite detectable albeit low
activity in cell-based assays (Figure 4c). Despite the high degree
of correlation between the thermal shift and cell-based assays
(Supporting Information, Figure 4), compounds that exhibit
very low ΔTm may exhibit measurable inhibition in cells at
moderately high concentrations, potentially due to cytotoxicity
Figure 3. Potency and selectivity of compound 15 derivatives based on thermal shift, biochemical kinase activity, and ligand induced transcriptional
activity assays. (a) The 2-aminopyridine scaﬀold of 15. (b) Modiﬁcations to the ATP-binding pocket hydrophobic domain (R2) of compound 15. (c)
Thermal shift (ΔTm), biochemical enzymatic inhibition (IC50) for ALK2 and ALK5 kinase proteins, and inhibition of cell-based BMP6 and TGF-β1-
induced transcriptional activity (IC50) by compound 15 derivatives (nd = not determined). (d) Correlation of thermal shift and cell-based BMP/
TGF-β inhibition assays.
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at high concentrations (>50 μM, Supporting Information,
Figure 5). Replacing the primary amine with hydrogen (26)
resulted in only a modest decline in potency and signiﬁcantly
increased selectivity for BMP6 versus TGF-β signaling,
suggesting that the primary amine hydrogen bond to the
hinge backbone is more critical for binding to ALK5 (D281)
than ALK2 (H284). Finally, we used two other small
substituents, e.g., chlorine (27) and methyl (10) groups to
explore the possibility that ALK2 is less sensitive than ALK5 to
substituents at this position. Although both compounds lost
potency relative to 26, there was a signiﬁcant increase in
selectivity for BMP over TGF-β signaling, with both showing
greater than 150-fold selectivity in cell-based assays. In
particular, 10 remained relatively potent with a biochemical
IC50 of 24 nM for ALK2, a cell-based IC50 for BMP6 of
approximately 100 nM, and 164-fold selectivity for BMP6
versus TGF-β1. The activities of compounds 15, 26, and 10 in
the thermal shift kinase assay as well as two diﬀerent cell-based
assays (ligand induced transcription and constitutively active
type I receptor transcriptional activity) are summarized in
Supporting Information, Table 2. In each of the various assays,
compound 10 (LDN-214117) exhibited improved selectivity
for ALK2 versus ALK5 signaling, consistent with a high degree
of selectivity for BMP versus TGF-β signaling. In fact, when the
activity of 10 was measured against closely related BMP type I
receptors ALK1−3 via kinase assays, it appeared to inhibit
ALK2 more potently than ALK3 by more than 40-fold (Figure
6a), a degree of selectivity which rivals previously reported
compound LDN-212854.21 We tested whether or not
compounds with improved receptor selectivity such as 10 or
26 might also exhibit more selective inhibition of BMP ligands.
We found that both of these compounds impacted the
transcriptional activity of a BMP-responsive luciferase reporter
(BRE-Luc) in response to BMP6, a known ALK2 ligand, more
potently than that of BMP2 or BMP4, classic ligands of ALK3
(Figure 6b−d).35 In fact, compound 10 inhibited BMP6
preferentially to BMP2 and BMP4 by approximately 10-fold,
whereas K02288 and compound 15 inhibited BMP2, -4, and -6
with equal potency. These data support the concept that
increased selectivity of 10 and 26 for ALK2 translates into
increased selectivity for the activity of ligands which signal
primarily through ALK2, a class which include BMP6 and
BMP7.36 These results further highlight that the 2-position of
the pyridine in the K02288 series can be exploited to achieve
reasonably potent and highly selective BMP inhibitors,
presumably via optimization of hinge domain interactions.
SAR of K02288 and LDN-193189 Hybrid Molecules. We
previously described a highly selective pyrazolo[1,5-a]-
pyrimidine based BMP type I receptor kinase inhibitor LDN-
212854 that exhibited biased activity for ALK2. This selectivity
was achieved by a 5-quinoline moiety that interacts with the
same hydrophobic pocket as the 3,4,5-trimethoxy group of
K02288. With this in mind, we synthesized several derivatives
of 15 that replaced the 3,4,5-trimethoxyphenyl with 4- or 5-
Figure 4. Potency and selectivity of K02288 derivatives based on thermal shift, biochemical kinase activity, and ligand induced transcriptional activity
assays. (a) The 2-aminopyridine scaﬀold of 15. (b) Modiﬁcations to the primary amine kinase hinge binding domain (R3) of compound 15. (c)
Thermal shift (ΔTm), biochemical enzymatic inhibition (IC50) for ALK2 and ALK5 kinase proteins, and inhibition of cell-based BMP6 and TGF-β1-
induced transcriptional activity (IC50) by compound 15 derivatives (nd = not determined). (d) Correlation of thermal shift and cell-based BMP/
TGF-β inhibition assays.
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quinolines (Figure 5a). As expected, the 5-quinoline (31)
demonstrated substantially increased selectivity for BMP versus
TGF-β inhibition (Figure 5b). However, all of these
compounds were substantially less potent than 15. Modeling
of these 5-quinoline substituted compounds in the ATP-
binding pocket suggested that binding to the kinase hinge by
the 2-aminopyridine scaﬀold may constrain the quinoline
moiety to a suboptimal position as compared to the
pyrazolo[1,5a]pyrimidine scaﬀolds (Supporting Information,
Figure 6). Conversely, replacing the 5-quinoline of LDN-
212854 with the 3,4,5-trimethoxyphenyl of K02288 yielded 32
that demonstrated potent BMP6 inhibitory activity but with
less selectivity. Finally, hypothesizing that two individual
changes yielding improvements in selectivity might synergize,
we combined the substitutions of the 2-amino group with
hydrogen and the 3,5-dimethoxy group found in 26 and 17 to
yield 33. Although this molecule demonstrated improved
selectivity it had considerably less potency.
Kinome-Wide Selectivity. We previously reported the
kinome-wide selectivity for both K02288 and LDN-193189,
showing that K02288 has a more selective proﬁle with fewer
oﬀ-target kinases inhibited at low (0.1 μM) and high (1.0 μM)
concentrations.21,23 We sought to determine the kinome-wide
selectivity of K02288 derivative compounds 10 (LDN-214117)
and 15, via enzymatic kinase proﬁling of approximately 200
kinases, summarized in the kinome dendrogram shown in
Figure 7. The kinase most highly inhibited by compound 10
(LDN-214117) was ALK2, followed by TNIK, RIPK2, and
ABL1 (detailed results of kinome proﬁling provided in
Supporting Information, Table 3). Although less potent than
15, compound 10 (LDN-214117) demonstrated signiﬁcant
improvement in selectivity across the kinome. At 100 nM and 1
μM, compound 10 inhibited only 0.5% and 3.6% of kinases
proﬁled by more than 50%, whereas compound 15 inhibited
2.1% and 14.4% of kinases proﬁled, respectively. Compound 10
thus exhibited improved kinome selectivity than that previously
reported for LDN-193189, LDN-212854, or K02288.21,23
FOP Mutations and Inhibitor Binding. The majority of
individuals with FOP harbor the R206H germline mutation
aﬀecting the glycine−serine (GS-) rich regulatory domain of
ALK2.9,37−39 While several of the other known FOP-causing
mutations also involve residues of the GS-domain (i.e., L196P,
R202I, and Q207E), several aﬀect important regulatory sites
within the kinase domain (i.e., G328E/R/W, R258S, G356D,
and R375P).11−14,23,40 A subset of both GS-domain and kinase
domain mutations associated with FOP have also been found to
arise somatically in 20−30% of DIPG tumor tissues, frequently
in combination with mutations aﬀecting the loci encoding
histone H3.115−18
We and others have shown that much of the enhanced
cellular activity of various FOP-causing ALK2 mutants is
attributable to diﬀerential regulation of the signaling pathway,
i.e., impaired interactions with kinase regulatory protein
FKBP12, and diﬀerential basal versus ligand-induced signaling
activity.40,41 However, there is the possibility that ALK2
mutants have intrinsic diﬀerences in their enzymatic function,
Figure 5. Potency and selectivity of K02288 derivatives based on thermal shift, biochemical kinase activity, and ligand induced transcriptional activity
assays. (a) Structure of hybrid derivative molecules. (b) Thermal shift (ΔTm), biochemical enzymatic inhibition (IC50) for ALK2 and ALK5 kinase
proteins, and inhibition of cell-based BMP6 and TGF-β1-induced transcriptional activity (IC50) by hybrid molecules (nd = not determined). (c)
Correlation of thermal shift and cell-based BMP/TGF-β inhibition assays.
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which could manifest as diﬀerences in aﬃnity for ATP and
altered Km, with implications for their cellular activity and
susceptibility to inhibitors. We tested this directly by measuring
the Km for ATP of wild-type ALK2 and four FOP-causing
ALK2 mutants (L196P, Q207E, G328E, and R258S). The Km
values for wild type and mutant ALK2 were between 16 and 48
μM (Supporting Information, Table 4). Importantly, none of
the FOP-causing mutants exhibited enhanced aﬃnity for ATP
as compared with wild-type ALK2. Because ATP concen-
trations within cells vary from 1−10 mM,42 far in excess of the
calculated Km values, these slight diﬀerences in Km would likely
be inconsequential in cells.
A related, long-standing, and clinically relevant question in
the FOP ﬁeld has been whether mutant ALK2 proteins might
exhibit diﬀerential inhibition by, or distinct aﬃnity for,
particular kinase inhibitors, and if so, whether highly speciﬁc
inhibitors could be engineered to target selectively the activity
of these activated mutant proteins. We sought to answer this
question by probing a panel of seven representative mutant
ALK2 proteins with the library of K02288 derivatives
displaying varying potency against wild-type ALK2 using a
thermal shift kinase assay. We found a highly linear correlation
(r2 = 0.94−0.99) between the thermal shift induced by these
derivatives with wild-type vs mutant ALK2 proteins (Figure 8).
Figure 6. LDN-214117 exhibits selectivity for ALK2-mediated BMP signaling. (a) 10 (LDN-214117) demonstrates selective inhibition of ALK2 and
ALK1 in preference to ALK3 kinase activity. (b) In a cell-based assay measuring BMP-mediated transcription (BRE-Luciferase), K02288 (b) and 15
(c) exhibit relatively limited selectivity for diverse BMP ligands, whereas 26 (d) and 10 (e) exhibit relatively selective inhibition of BMP6 versus
BMP2 or BMP4, consistent with selective inhibition of ALK2- versus ALK3-mediated signaling, respectively.
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These results suggest that inhibitors engineered or identiﬁed
against wild-type or mutant ALK2 proteins will have
interchangeable activity against diverse mutant proteins found
in FOP or DIPG. Conversely, these results would preclude the
development of ATP-competitive ALK2 inhibitors which
selectively target mutant proteins. The pathogenicity of
activating mutations of ACVR1 has been well-established for
FOP, and thus the development of highly selective inhibitors is
an important step in validating ALK2 as a feasible clinical target.
While the presence of ACVR1 mutations appears to be
associated with increased downstream BMP signaling and
transcriptional activity in DIPG tumors,16,18 further work will
need to be performed to determine whether or not these
mutations contribute to the initiation or progression of tumors
in DIPG. The identiﬁcation of selective inhibitors of ALK2 may
help to elucidate the mechanisms of DIPG tumorigenicity and
could potentially be therapeutic if a contribution of BMP
signaling is conﬁrmed.
Cytotoxicity of Kinase Inhibitors. We next sought to
determine the cytotoxicity of these derivatives and to compare
them to many of the current FDA approved kinase inhibitors
(Figure 9). Because hepatotoxicity is one of the most common
reasons for withdrawal of approved drugs, we used HEPG2
cells for evaluation of cytotoxicity.43 Compounds were tested in
a large concentration range (1−100 μM) for 4 and 24 h. Upon
the basis of residual cell viability after treatment, compounds
were categorized as having low (>75%), medium (25−75%), or
high (<25%) cytotoxicity. Of the 12 approved kinase inhibitors
tested, only one exhibited high cytotoxicity at 100 μM after 4 h
of incubation, whereas six of the 28 derivatives in our K02288
library exhibited high cytotoxicity after 4 h. Over a 24 h period
four of 12 approved kinase inhibitors showed high cytotoxicity
at 100 μM, whereas 23 of the 28 K02288 derivatives showed
high toxicity. However, 10, which demonstrated good potency
and high BMP selectivity, exhibited very low cytotoxicity. In
fact, cytotoxicity was not correlated with BMP signaling
inhibition, TGF-β inhibition, nor selectivity for BMP versus
TGF-β signaling (Supporting Information, Figure 5). For
example, the highly potent BMP inhibitor 11 was also
noncytotoxic, suggesting that the mechanisms of cytotoxicity
within this series of compounds do not result from eﬀects on
BMP or TGF-β signaling.
Figure 7. Compound 10 exhibits increased kinome selectivity. Kinome dendrogram plot for compound 15 (LDN-212838) (a) and compound 10
(LDN-214117) (b) showing an improved selectivity proﬁle for 10 for BMP type I receptor kinases.
Figure 8. FOP-causing ALK2 mutations do not aﬀect inhibitor
binding. (a) Strong correlation of thermal shift data for ATP
competitive kinase inhibitors binding to wild-type ALK2 versus
known FOP causing GS-domain mutations of ALK2 and (b) known
FOP causing kinase domain mutations suggests the potency of ATP
competitive inhibitors are not aﬀected by these disease causing
mutations. m = slope, R2 = correlation coeﬃcient.
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Structural Basis of Inhibitor Binding. A number of the most
promising derivatives were tested for co-crystallization with
ALK2 to further understand the binding mode and SAR.
Diﬀraction quality crystals were obtained in the presence of 26,
and the structure of the complex was solved at 2.6 Å resolution
(Figure 9; see Supporting Information, Table 5 for data
collection and reﬁnement statistics).
In the co-crystal structure, 26 was bound to the kinase hinge
region as shown previously for the parent molecule K02288
(Figure 10).23 Both molecules established an ATP-mimetic
hydrogen bond between the pyridine nitrogen and the amide of
H286. Replacement of the 3-phenol and primary amine with 4-
phenylpiperazine and hydrogen, respectively, did not alter the
overall position of 26 but resulted in the loss of the hinge
hydrogen bond interaction between the primary amine and the
carbonyl of H284. The conserved 3,4,5-trimethoxyphenyl
provided hydrophobic interaction as well as a water-mediated
hydrogen bond to the catalytic lysine K235. Docking of 10
produced a similar binding mode, with no signiﬁcant change
resulting from the introduction of the methyl group. Overall,
the ATP pocket occupied by these 3,5-diarylpyridines was
similar to the pyrazolo[1,5-a]pyrimidine scaﬀold of LDN-
193189. However, the two series diﬀered slightly in their hinge
binding orientation resulting in shifts in the position of their
respective hydrophobic pocket groups as well as the shared 4-
phenylpiperazine (Supporting Information, Figure 6).
The selectivity of these molecules for ALK2 over ALK5 likely
results from dynamic conformational diﬀerences between these
kinases as well as the modest number of sequence changes in
the ATP pocket. Perhaps as a result of its smaller serine
gatekeeper residue, the ATP pocket in many ALK5 co-crystal
structures shows a more open conformation than those of
ALK2 with a noticeable movement of the N-lobe away from the
C-lobe (Supporting Information, Figure 1). Such conforma-
tional diﬀerences are expected to change the shape, volume,
and dynamics of the ATP pocket to impact inhibitor binding.
■ CONCLUSION
We have developed a library of BMP receptor kinase inhibitors
based on the 2-aminopyridine scaﬀold of K02288. This library
allowed us to explore the SAR of various functional groups and
resulted in the creation of several potent derivatives. Several of
these compounds demonstrated improved activity, selectivity,
or both, measured using a thermal shift assay, an enzymatic
assay, and cellular assays of BMP/TGF-β-induced transcription,
Figure 9. Cytotoxicity of FDA-approved kinase inhibitor compounds
as compared with BMP inhibitor compounds. Cultured HepG2 cells
were exposed to 1, 10, and 100 μM concentrations of compounds for 4
and 24 h. The average cell viability of three experiments is shown
(green indicating >75%, orange indicating 25−75%, and red <25%
viability).
Figure 10. Binding mode of 26. (a) The inhibitor (yellow) forms a single hydrogen bond to the hinge amide of H286 as well as a water-mediated
bond to the catalytic lysine K235. (b) Plot of the interactions of the inhibitor (purple) in the binding pocket of ALK2. The plot was generated by
LigPlot+.54
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thus overcoming the limited potency of the parent compound
in cells.
We determined that the solvent-exposed 3-phenol sub-
stituent of K02288 was responsible for its unexpectedly low
activity in cells as compared to kinase assay IC50. By replacing
this group with either a 4-phenol or 4-phenylpiperazine, we
were able to improve potency in cellular assays compared to
K02288 by 20- and 100-fold, respectively. We previously
reported that the 3,4,5-trimethoxyphenyl occupies the rear
hydrophobic pocket to provide excellent shape complementar-
ity and forms water-mediated hydrogen bonds to the catalytic
lysine residue (K235).23 Here we found that the 4-methoxy
group was largely dispensable, while the 3- or 5-methoxy
groups were more critical for maintaining potency. The balance
of selectivity and potency found in the 3,5-dimethoxy derivative
17 suggests further medicinal chemistry optimization is possible
and could yield further insights into the determinants of activity
in the hydrophobic pocket. Within the 2-aminopyridine core,
we found that the primary amine was more critical for TGF-β
than BMP binding aﬃnity and could be replaced with a
nonpolar methyl group to generate a highly BMP selective
compound 10 (LDN-214117), which is signiﬁcantly biased
toward ALK2 and its cognate ligands including BMP6 and also
demonstrates a high degree of kinome selectivity and low
cytotoxicity. Finally, we concluded that replacing the 3,4,5-
trimethoxyphenyl with quinolines as previously described for
pyrazolopyrimidine compounds (LDN-193189 and LDN-
212854) was not an eﬀective strategy and resulted in a
substantial loss of potency.
We used this structurally diverse compound series with
varying degrees of potency to explore the eﬀect of FOP-causing
mutations on inhibitor binding aﬃnity. These compounds
exhibited nearly identical binding aﬃnity for wild-type ALK2
and each of the FOP-causing mutants tested, demonstrating
that ATP-competitive inhibitors active against wild-type protein
will eﬀectively target diverse FOP mutants. While this result
would also suggest that ATP-competitive inhibitors cannot
speciﬁcally target mutant versus wild-type ALK2, one could
envision molecules targeting allosteric sites unique to mutant
proteins to potentially achieve speciﬁcity.
The novel series of compounds reported here constitutes an
alternative pharmacophore with discrete properties, including
distinct kinome selectivity, as compared to the pyrazolopyr-
imidine class of BMP inhibitors.23 Several of these compounds,
including 10 (LDN-214117), may be useful as highly selective
probes of BMP-mediated cellular physiology that may provide a
useful complement to the dorsomorphin class of compounds.
Furthermore, this class of BMP inhibitors oﬀers a structurally
distinct template for the development of therapeutics for the
treatment of BMP signaling-mediated diseases such as FOP.
■ EXPERIMENTAL SECTION
Chemistry Material and Methods. Unless otherwise noted, all
reagents and solvents were purchased from commercial sources and
used without further puriﬁcation. The NMR spectra were obtained
using a 300 or 500 MHz spectrometer. All 1H NMR spectra are
reported in δ units (ppm) and were recorded in CDCl3 and referenced
to the peak for tetramethylsilane (TMS) or in DMSO. Coupling
constants (J) are reported in hertz. Column chromatography was
performed utilizing a CombiFlash Sg 100c separation system with
RediSep disposable silica gel columns. High-resolution mass spectra
were obtained by using AccuTOF with a DART source. All test
compounds reported in this manuscript had a purity ≥95% as
determined by high-performance liquid chromatography (HPLC)
analyses using an instrument equipped with a quaternary pump and a
SB-C8 column (30 mm × 4.6 mm, 3.5 μm). UV absorption was
monitored at λ = 254 nm. The injection volume was 5 μL. HPLC
gradient went from 5% acetonitrile/95% water to 95% acetonitrile/5%
water (both solvents contain 0.1% triﬂuoroacetic acid) over 1.9 min
with a total run time of 3.0 min and a ﬂow rate of 3.0 mL/min.
Synthesis of 2-Amino-5-bromo-3-(3,4,5-trimethoxyphenyl)-
pyridine (2). A mixture of 5-bromo-3-iodopyridin-2-amine (386 mg,
1.30 mmol), 3,4,5-trimethoxyphenylboronic acid (275 mg, 1.30
mmol), and Pd(PPh3)4 (180 mg, 0.156 mmol) were added to a
sealed tube. The tube was evacuated and backﬁlled with argon (3
cycles). Acetonitrile (6.0 mL) and DMF (2.5 mL) were added by
syringe at room temperature, followed by (1 M) aqueous Na2CO3 (2.6
mL, 2.60 mmol). After being stirred at 90 °C for about 8 h, the
reaction mixture was ﬁltered and concentrated. The residue was
puriﬁed by ﬂash column chromatography to give 2 as white solid (235
mg, 80%). 1H NMR (500 MHz, CDCl3) δ 8.11 (d, J = 2.5 Hz, 1H),
7.48 (d, J = 2.5 Hz, 1H), 6.62 (s, 2H), 3.90 (s, 3H), 3.88 (s, 6H). MS
(ESI): 339.0 [M]+.
Genera l Synthes i s of 2-Amino-5-ary l -3 - (3 ,4 ,5 -
trimethoxyphenyl)pyridines (3). To a solution of 2 (1.0 equiv),
an aryl boronic acid (1.1 equiv), and Pd(PPh3)4 (0.12 equiv) in DME,
(1 M) aqueous Na2CO3 (2.0 equiv) was added. The reaction mixture
was stirred under an argon atmosphere at 90 °C for 8 h. The reaction
mixture was ﬁltered and then concentrated. The residue was puriﬁed
by ﬂash column chromatography, eluting with a mixture of
cyclohexane and EtOAc to give products 3.
3-(6-Amino-5-(3,4,5-trimethoxyphenyl)pyridin-3-yl)phenol
(K02288). Yield: 40%. 1H NMR (500 MHz, CDCl3) δ 8.48 (d, J = 2.0
Hz, 1H), 7.69 (d, J = 2.0 Hz, 1H), 7.34 (t, J = 7.5 Hz, 1H), 7.20 (d, J =
2.0 Hz, 1H), 7.08 (d, J = 8.0 Hz, 1H), 6.90 (dd, J = 2.0, 7.0 Hz, 1H),
6.68 (s, 2H), 4.81 (br, 2H), 3.91 (s, 3H), 3.89 (s, 6H). HRMS (ESI)
calcd for C20H21N2O4 353.1501 [M + H]
+; found 353.1462; purity
95.6% (tR 1.35 min).
4-(6-Amino-5-(3,4,5-trimethoxyphenyl)pyridin-3-yl)phenol
(11). Yield: 42%. 1H NMR (500 MHz, CDCl3) δ 8.27 (d, J = 2.5 Hz,
1H), 7.57 (d, J = 2.5 Hz, 1H), 7.43−7.41 (m, 2H), 6.92−6.90 (m,
2H), 6.90 (dd, J = 2.0, 7.0 Hz, 1H), 6.69 (s, 2H), 4.64 (br, 2H), 3.91
(s, 3H), 3.89 (s, 6H). HRMS (ESI) calcd for C20H21N2O4 353.1501
[M + H]+; found 353.1490; purity 100.0% (tR 1.32 min).
4-(6-Amino-5-(3,4,5-trimethoxyphenyl)pyridin-3-yl)-2-me-
thoxyphenol (12). Yield: 70%. 1H NMR (500 MHz, CDCl3) δ 8.27
(d, J = 2.5 Hz, 1H), 7.56 (d, J = 2.5 Hz, 1H), 7.06−6.98 (m, 3H), 6.70
(s, 2H), 4.65 (br, 2H), 3.95 (s, 3H), 3.91 (s, 3H), 3.89 (s, 6H). HRMS
(ESI) calcd for C21H23N2O5 383.1607 [M + H]
+; found 383.1603;
purity 98.3% (tR 1.34 min).
N-(3-(6-Amino-5-(3,4,5-trimethoxyphenyl)pyridin-3-yl)-
phenyl)methanesulfonamide (13). Yield: 85%. 1H NMR (500
MHz, CDCl3) δ 8.89 (br, 1H), 8.39 (d, J = 2.5 Hz, 1H), 7.61 (d, J =
1.5 Hz, 1H), 7.47−7.40 (m, 3H), 7.34 (dt, J = 1.5, 7.5 Hz, 1H), 6.68
(s, 2H), 5.19 (br, 2H), 3.91 (s, 3H), 3.90 (s, 6H) 3.06 (s, 3H). HRMS
(ESI) calcd for C21H24N3O5S 430.1437 [M + H]
+; found 430.1412;
purity 99.3% (tR 1.34 min).
General Synthesis of 3-Aryl-5-bromopyridines (5). A mixture
of 5-bromo-3-iodopyridin-2-amine (1.0 equiv), arylboronic acid (1.0
equiv), and Pd(PPh3)4 (0.12 equiv) was added to a sealed tube. The
tube was evacuated and backﬁlled with argon (3 cycles). Acetonitrile
and DMF (3:1 mL) were added by syringe at room temperature,
followed by (1 M) aqueous Na2CO3 (2.0 equiv). After being stirred at
90 °C for about 8 h, the reaction mixture was ﬁltered and
concentrated. The residue was puriﬁed by ﬂash column chromatog-
raphy to give 5.
General Synthesis of 3-Aryl-5-((N-Boc)-piperazinylphenyl)-
pyridines (6). To a solution of 5 (1.0 equiv), [(N-Boc)piperazin-1-
yl]phenylboronic acid pinacol ester (1.1 equiv), and Pd(PPh3)4 (0.12
equiv) in DME, (1 M) aqueous Na2CO3 (2.0 equiv) was added. The
reaction mixture was stirred under argon atmosphere at 90 °C for 8 h.
The reaction mixture was ﬁltered and concentrated. The residue was
puriﬁed by ﬂash column chromatography, eluting with a mixture
cyclohexane/EtOAc to give 6.
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General Synthesis of 3-Aryl-5-(piperazinylphenyl)pyridines
(7). To a stirring solution of the 6 (0.01 mmol) in dry CH2Cl2 (2 mL)
at 0 °C, triﬂuoroacetic acid (0.2 mL) was slowly added and the
reaction mixture was stirred overnight at room temperature. The
mixture was concentrated under vacuum. The residue was suspected in
ethyl acetate (10 mL), and then a saturated NaHCO3 solution was
added to adjust the pH to 7 at 0 °C. The mixture was extracted with
ethyl acetate (3 × 10 mL). The combined organic layer was dried over
anhydrous Na2SO4, ﬁltered, and concentrated in vacuo. The remaining
residue was subjected to column chromatography to furnish 7 as a
white to light-yellow foam.
5-(3-(Piperazin-1-yl)phenyl)-3-(3,4,5-trimethoxyphenyl)-
pyridin-2-amine (14). Yield: 82%. 1H NMR (500 MHz, CDCl3) δ
8.31 (d, J = 2.5 Hz, 1H), 7.61 (d, J = 2.5 Hz, 1H), 7.35 (d, J = 8.0 Hz,
1H), 7.07 (t, J = 2.0 Hz, 1H), 7.04−7.03 (m, 1H), 6.92−6.90 (m, 1H),
6.70 (s, 2H), 4.68 (br, 2H), 3.91 (s, 3H), 3.89 (s, 6H), 3.21−3.19 (m,
4H), 3.06−3.04 (m, 4H). HRMS (ESI) calcd for C24H28N4O3
421.2240 [M + H]+; found 421.2215; purity 98.7% (tR 1.12 min).
5-(4-(Piperazin-1-yl)phenyl)-3-(3,4,5-trimethoxyphenyl)-
pyridin-2-amine (15). Yield: 77%. 1H NMR (500 MHz, CDCl3) δ
8.29 (d, J = 2.0 Hz, 1H), 7.58 (d, J = 2.5 Hz, 1H), 7.47−7.45 (m, 2H),
7.00−6.98 (m, 2H), 6.70 (s, 2H), 4.61 (br, 2H), 3.91 (s, 3H), 3.89 (s,
6H), 3.26−3.24 (m, 0.6H) and 3.20−3.18 (m, 3.4H) due to rotamer,
3.07−3.05 (m, 3.4H) and 2.72−2.70 (m, 0.6H) due to rotamer.
HRMS (ESI) calcd for C24H28N4O3 421.2240 [M + H]
+; found
421.2259; purity 98.6% (tR 1.05 min).
3-(3,4-Dimethoxyphenyl)-5-(4-(piperazin-1-yl)phenyl)-
pyridin-2-amine (16). Yield: 80%. 1H NMR (500 MHz, CDCl3) δ
8.28 (d, J = 2.5 Hz, 1H), 7.57 (d, J = 2.0 Hz, 1H), 7.47−7.45 (m, 2H),
7.06−7.04 (m, 1H), 7.01−6.97 (m, 4H), 4.58 (br, 2 H), 3.94 (s, 3 H),
3.91 (s, 3 H), 3.26−3.24 (m, 0.3H) and 3.20−3.18 (m, 3.7H) due to
rotamer, 3.07−3.05 (m, 3.7H) and 2.72−2.70 (m, 0.3H) due to
rotamer. HRMS (ESI) calcd for C23H27N4O2 391.2134 [M + H]
+;
found 391.2142; purity 97.9% (tR 1.08 min).
3-(3,5-Dimethoxyphenyl)-5-(4-(piperazin-1-yl)phenyl)-
pyridin-2-amine (17). Yield: 85%. 1H NMR (500 MHz, CDCl3) δ
8.27 (d, J = 2.5 Hz, 1H), 7.59 (d, J = 2.5 Hz, 1H), 7.46−7.44 (m, 2H),
7.00−6.98 (m, 2H), 6.63 (d, J = 2.0 Hz, 2H), 6.50 (t, J = 2.5 Hz, 1H),
4.76 (br, 2H), 3.83 (s, 6H), 3.21−3.19 (m, 4H), 3.08−3.06 (m, 4H).
HRMS (ESI) calcd for C23H27N4O2 391.2134 [M + H]
+; found
391.2159; purity 97.7% (tR 1.16 min).
3-(3-Methoxyphenyl)-5-(4-(piperazin-1-yl)phenyl)pyridin-2-
amine (18). Yield: 82%. 1H NMR (500 MHz, CDCl3) δ 8.28 (d, J =
2.0 Hz, 1H), 7.59 (d, J = 2.0 Hz, 1H), 7.46−7.44 (m, 2H), 7.41 (t, J =
8.0 Hz, 1H), 7.09−7.07 (m, 1H), 7.03 (t, J = 2.0 Hz, 1H), 7.00−6.98
(m, 2H), 6.95 (dd, J = 2.0, 8.5 Hz, 1H), 4.69 (br, 2 H), 3.85 (s, 3H),
3.26−3.24 (m, 0.7H) and 3.22−3.20 (m, 3.3H) due to rotamer, 3.09−
3.07 (m, 3.3H) and 2.72−2.70 (m, 0.7H) due to rotamer. HRMS
(ESI) calcd for C22H25N4O 361.2028 [M + H]
+; found 361.2043;
purity 97.5% (tR 1.16 min).
3-(2,3-Dihydrobenzo[b][1,4]dioxin-6-yl)-5-(4-(piperazin-1-
yl)phenyl)pyridin-2-amine (19). Yield: 80%. 1H NMR (500 MHz,
CDCl3) δ 8.25 (d, J = 2.5 Hz, 1H), 7.54 (d, J = 2.0 Hz, 1H), 7.45−7.43
(m, 2H), 7.02−7.01 (m, 1H), 6.99−6.96 (m, 4H), 4.63 (br, 2H), 4.31
(s, 4 H), 3.25−3.23 (m, 0.8H) and 3.20−3.18 (m, 3.2H) due to
rotamer, 3.07−3.05 (m, 3.2H) and 2.72−2.70 (m, 0.8H) due to
rotamer. HRMS (ESI) calcd for C23H25N4O2 389.1978 [M + H]
+;
found 389.2003; purity 97.0% (tR 1.16 min).
3-(4-Methoxyphenyl)-5-(4-(piperazin-1-yl)phenyl)pyridin-2-
amine (20). Yield: 78%. 1H NMR (500 MHz, CDCl3) δ 8.27 (d, J =
2.5 Hz, 1H), 7.55 (d, J = 2.0 Hz, 1H), 7.46−7.42 (m, 4H), 7.02−6.98
(m, 4H), 4.55 (br, 2H), 3.87 (s, 3H), 3.19−3.18 (m, 4H), 3.07−3.05
(m, 4H). HRMS (ESI) calcd for C22H25N4O 361.2028 [M + H]
+;
found 361.2055; purity 97.7% (tR 1.20 min).
3-(3-Isopropoxyphenyl)-5-(4-(piperazin-1-yl)phenyl)pyridin-
2-amine (21). Yield: 80%. 1H NMR (300 MHz, CDCl3) δ 8.29 (d, J =
2.4 Hz, 1H), 7.58 (d, J = 2.4 Hz, 1H), 7.47−7.44 (m, 2H), 7.39 (d, J =
8.4 Hz, 1H), 7.06−6.97 (m, 4H), 6.93−6.89 (m, 1H), 4.63−4.55 (m,
3H), 3.20−3.17 (m, 4H), 3.07−3.04 (m, 4H), 1.37 (d, J = 6.0 Hz,
6H). HRMS (ESI) calcd for C24H29N4O 389.2341 [M + H]
+; found
389.2362; purity 100.0% (tR 1.16 min).
3-(4-Chloro-3-methoxyphenyl)-5-(4-(piperazin-1-yl)phenyl)-
pyridin-2-amine (22). Yield: 82%. 1H NMR (300 MHz, CDCl3) δ
8.27 (d, J = 2.1 Hz, 1H), 7.57 (d, J = 2.4 Hz, 1H), 7.48−7.44 (m, 3H),
7.04−6.98 (m, 4H), 4.83 (br, 2H), 3.94 (s, 3H), 3.32−3.29 (m, 3.6H)
and 3.26−3.22 (m, 0.4H) due to rotamer, 3.18−3.15 (m, 3.6H) and
2.74−2.69 (m, 0.4H) due to rotamer. HRMS (ESI) calcd for
C22H24ClN4O 395.1639 [M + H]
+; found 395.1647; purity 96.6%
(tR 1.18 min).
3-(3-Methoxy-4-methylphenyl)-5-(4-(piperazin-1-yl)phenyl)-
pyridin-2-amine (23). Yield: 84%. 1H NMR (300 MHz, CDCl3) δ
8.28 (d, J = 2.4 Hz, 1H), 7.58 (d, J = 2.4 Hz, 1H), 7.47−7.44 (m, 2H),
7.24−7.21 (m, 1H), 7.00−6.97 (m, 3H), 6.93 (d, J = 1.5 Hz, 1H), 4.65
(br, 2H), 3.85 (s, 3H), 3.20−3.16 (m, 4H), 3.07−3.03 (m, 4H), 2.67
(s, 3H). HRMS (ESI) calcd for C23H27N4O 375.2185 [M + H]
+;
found 375.2189; purity 100.0% (tR 1.16 min).
N -Methy l -5 - ( 4 - (p iperaz in -1 -y l )pheny l ) -3 - ( 3 , 4 , 5 -
trimethoxyphenyl)pyridin-2-amine (24). Yield: 92%. 1H NMR
(500 MHz, CDCl3) δ 8.39 (d, J = 2.0 Hz, 1H), 7.50 (d, J = 2.5 Hz,
1H), 7.46−7.45 (m, 2H), 7.00−6.98 (m, 2H), 6.63 (s, 2H), 4.67 (q, J
= 5.0 Hz, 1H), 3.91 (s, 3H), 3.88 (s, 6H), 3.25−3.22 (m, 0.6H) and
3.20−3.18 (m, 3.4H) due to rotamer, 3.08−3.06 (m, 3.6H) and 2.72−
2.70 (m, 0.4H) due to rotamer, 3.01 (d, J = 5.0 Hz, 3H). HRMS (ESI)
calcd for C25H31N4O3 435.2396 [M + H]
+; found 435.2396; purity
98.9% (tR 1.10 min).
N ,N-Dimethyl-5-(4-(piperazin-1-yl)phenyl)-3-(3,4,5-
trimethoxyphenyl)pyridin-2-amine (25). Yield: 90%. 1H NMR
(500 MHz, CDCl3) δ 8.40 (d, J = 2.0 Hz, 1H), 7.62 (d, J = 2.5 Hz,
1H), 7.48−7.46 (m, 2H), 7.00−6.99 (m, 2H), 6.76 (s, 2H), 3.90 (s,
3H), 3.88 (s, 6H), 3.21−3.19 (m, 4H), 3.07−3.05 (m, 4H), 2.78 (s,
6H). HRMS (ESI) calcd for C26H33N4O3 449.2553 [M + H]
+; found
449.2575; purity 97.8% (tR 1.14 min).
1-(4-(5-(3,4,5-Trimethoxyphenyl)pyridin-3-yl)phenyl)-
piperazine (26). Yield: 95%. 1H NMR (500 MHz, CDCl3) δ 8.78 (d,
J = 2.0 Hz, 1H), 8.71 (d, J = 2.5 Hz, 1H), 7.95 (t, J = 2.5 Hz, 1H),
7.58−7.56 (m, 2H), 7.06−7.04 (m, 2H), 6.80 (s, 2H), 3.95 (s, 6H),
3.91 (s, 3H), 3.25−3.23 (m, 4H), 3.08−3.06 (m, 4H). HRMS (ESI)
calcd for C24H28N3O3 406.2131 [M + H]
+; found 406.2142; purity
100.0% (tR 1.20 min).
1-(4-(6-Chloro-5-(3,4,5-trimethoxyphenyl)pyridin-3-yl)-
phenyl)piperazine (27). Yield: 94%. 1H NMR (300 MHz, CDCl3) δ
8.57 (d, J = 2.4 Hz, 1H), 7.83 (d, J = 2.7 Hz, 1H), 7.53−7.50 (m, 2H),
7.03−7.00 (m, 2H), 6.70 (s, 2H), 3.92 (s, 3H), 3.90 (s, 6H), 3.32−
3.28 (m, 0.5H) and 3.27−3.24 (m, 3.5H) due to rotamer, 3.10−3.07
(m, 3.5H) and 2.75−2.69 (m, 0.5H) due to rotamer. HRMS (ESI)
calcd for C24H27ClN3O3 440.1741 [M + H]
+; found 440.1723; purity
95.6% (tR 1.42 min).
1-(4-(6-Methoxy-5-(3,4,5-trimethoxyphenyl)pyridin-3-yl)-
phenyl)piperazine (28). Yield: 79%. 1H NMR (500 MHz, CDCl3) δ
8.34 (d, J = 2.0 Hz, 1H), 7.78 (d, J = 2.5 Hz, 1H), 7.50−7.48 (m, 2H),
7.03−7.01 (m, 2H), 6.81 (s, 2H), 4.02 (s, 3H), 3.90 (s, 9H), 3.28−
3.26 (m, 0.3H) and 3.23−3.21 (m, 3.7H) due to rotamer, 3.08−3.07
(m, 3.7H) and 2.73−2.71 (m, 0.3H) due to rotamer. HRMS (ESI)
calcd for C25H29N3O4 436.2236 [M + H]
+; found 436.2265; purity
100.0% (tR 1.38 min).
5-(4-(Piperazin-1-yl)phenyl)-3-(quinolin-4-yl)pyridin-2-
amine (29). Yield: 79%. 1H NMR (500 MHz, CDCl3) δ 9.02 (d, J =
4.5 Hz, 1H), 8.46 (d, J = 2.5 Hz, 1H), 8.22 (d, J = 8.0 Hz, 1H), 7.79−
7.75 (m, 2H), 7.64 (d, J = 2.5 Hz, 1H), 7.57−7.53 (m, 1H), 7.48−7.43
(m, 3H), 7.01−6.98 (m, 2H), 4.34 (br, 2H), 3.25−3.23 (m, 0.6H) and
3.20−3.18 (m, 3.4H) due to rotamer, 3.07−3.05 (m, 3.4H) and 2.72−
2.70 (m, 0.6H) due to rotamer. HRMS (ESI) calcd for C24H24N5
382.2032 [M + H]+; found 382.1993; purity 97.7% (tR 1.04 min).
5-(3-(Piperazin-1-yl)phenyl)-3-(quinolin-4-yl)pyridin-2-
amine (30). Yield: 85%. 1H NMR (500 MHz, CDCl3) δ 9.03 (d, J =
4.0 Hz, 1H), 8.48 (s, 1 H), 8.22 (d, J = 8.0 Hz, 1H), 7.80−7.74 (m,
2H), 7.66 (s, 1 H), 7.57 (d, J = 8.0 Hz, 1H), 7.47−7.44 (m, 1H), 7.35
(t, J = 8.0 Hz, 1H), 7.07−7.03 (m, 2H), 6.92 (d, J = 8.5 Hz, 1H), 4.38
(br, 2 H), 3.26−3.22 (m, 1H) and 3.21−3.19 (m, 3H) due to rotamer,
3.05−3.04 (m, 3H) and 2.71−2.66 (m, 1H) due to rotamer. HRMS
(ESI) calcd for C24H24N5 382.2032 [M + H]
+; found 382.2024; purity
95.1% (tR 1.09 min).
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5-(4-(Piperazin-1-yl)phenyl)-3-(quinolin-5-yl)pyridin-2-
amine (31). Yield: 84%. 1H NMR (500 MHz, CDCl3) δ 8.98 (dd, J =
2.0, 4.5 Hz, 1H), 8.44 (d, J = 2.5 Hz, 1H), 8.21 (d, J = 9.0 Hz, 1H),
8.06−8.04 (m, 1H), 7.84−7.81 (m, 1H), 7.63 (d, J = 2.5 Hz, 1H),
7.59−7.58 (m, 1H), 7.48−7.46 (m, 2H), 7.41−7.39 (m, 1H), 7.00−
6.97 (m, 2H), 4.29 (br, 2 H), 3.25−3.23 (m, 0.4H) and 3.20−3.18 (m,
3.6H) due to rotamer, 3.06−3.04 (m, 3.6H) and 2.71−2.69 (m, 0.4H)
due to rotamer. HRMS (ESI) calcd for C24H24N5 382.2032 [M + H]
+;
found 382.2039; purity 95.2% (tR 0.97 min).
1-(4-(5-(3,5-Dimethoxyphenyl)pyridin-3-yl)phenyl)-
piperazine (33). Yield: 98%. 1H NMR (300 MHz, CDCl3) δ 8.79 (d,
J = 2.4 Hz, 1H), 8.73 (d, J = 2.4 Hz, 1H), 7.99 (t, J = 2.1 Hz, 1H),
7.57−7.54 (m, 2H), 7.04−7.02 (m, 2H), 6.76 (d, J = 1.8 Hz, 2H), 6.53
(t, J = 2.1 Hz, 1H), 3.86 (s, 6H), 3.23−3.21 (m, 4H), 3.06−3.04 (m,
4H). HRMS (ESI) calcd for C23H26N3O2 376.2025 [M + H]
+; found
376.2023; purity 100.0% (tR 1.26 min).
Synthesis of 1-(4-(6-Methyl-5-(3,4,5-trimethoxyphenyl)-
pyridin-3-yl)phenyl)piperazine (10). A mixture of N-Boc-4-(4-(6-
chloro-5-(3,4,5-trimethoxyphenyl)pyridin-3-yl)phenyl)piperazine (43
mg, 0.080 mmol), trimethylboroxine (46 μL, 0.32 mmol), Pd(PPh3)4
(19 mg, 0.016 mmol), and K2CO3 (22 mg, 0.16 mmol) were added to
a sealed tube. The tube was evacuated and backﬁlled with argon (3
cycles). 1,4-Dioxane (1.0 mL) was added by syringe at room
temperature. After being stirred at 110 °C for 8 h, the reaction
mixture was ﬁltered and concentrated. The residue puriﬁed by ﬂash
column chromatography to give 9 (40 mg, 96%). 1H NMR (300 MHz,
CDCl3) δ 8.70 (d, J = 2.4 Hz, 1H), 7.69 (d, J = 2.4 Hz, 1H), 7.54−7.51
(m, 2H), 7.02−6.99 (m, 2H), 6.55 (s, 2H), 3.91 (s, 3H), 3.88 (s, 6H),
3.61−3.58 (m, 4H), 3.21−3.18 (m, 4H), 2.55 (s, 3H), 1.48 (s, 9H).
MS (ESI): 519.5 [M]+. The carbamate protecting group of 9 (40 mg)
was removed using the general method previously described using
TFA to furnish 10 as a white foam (30 mg, 93%). 1H NMR (300
MHz, CDCl3) δ 8.71 (d, J = 2.1 Hz, 1H), 7.70 (d, J = 2.4 Hz, 1H),
7.55−7.52 (m, 2H), 7.03−7.00 (m, 2H), 6.56 (s, 2H), 3.92 (s, 3H),
3.89 (s, 6H), 3.24−3.20 (m, 4H), 3.08−3.05 (m, 4H), 2.55 (s, 3H).
HRMS (ESI) calcd for C25H30N3O3 420.2287 [M + H]
+; found
420.2295; purity 95.5% (tR 1.13 min).
Synthesis of 3-(3,4,5-Trimethoxyphenyl)-6-[4-(1-
piperazinyl)phenyl]pyrazolo[1,5-a]pyrimidine (32). This com-
pound was prepared using a reported methodology.9 1H NMR (500
MHz, DMSO) δ 9.38 (d, J = 2.0 Hz, 1H), 9.04 (d, J = 2.0 Hz, 1H),
8.80 (s, 1H), 7.75 (d, J = 9.0 Hz, 2H), 7.51 (s, 2H), 7.07 (d, J = 9.0
Hz, 1H), 3.88 (s, 6H), 3.70 (s, 3H), 3.25−3.18 (m, 4H), 2.92−2.90
(m, 4H). HRMS (ESI) calcd for C25H27N5O3 446.2192 [M + H]+;
found 446.2186; purity 100% (tR 1.43 min).
Thermal Shift Kinase Assay. Thermal melting experiments were
performed using a Real Time PCR machine Mx3005p (Stratagene)
with a protein concentration of 1−2 μM and 10 μM inhibitor as
described previously.44 Recombinant human kinases for DSF screening
were prepared by SGC using published methods.23
Protein Expression and Puriﬁcation. The human ALK2 kinase
domain, residues 201−499 including the activating mutation Q207D,
was subcloned into the vector pFB-LIC-Bse. Baculoviral expression
was performed in Sf9 insect cells at 27 °C, shaking at 110 rpm. Cells
were harvested at 72 h postinfection and resuspended in 50 mM
HEPES pH 7.5, 500 mM NaCl, 5 mM imidazole, 5% glycerol, 0.1 mM
TCEP, supplemented with protease inhibitor set V (Calbiochem).
Cells were lysed using a C5 high pressure homogenizer (Emulsiﬂex)
and the insoluble material excluded by centrifugation at 21000 rpm.
Nucleic acids were removed on a DEAE-cellulose column before
puriﬁcation of the N-terminally His-tagged ALK2 protein by Ni-
aﬃnity chromatography. The eluted protein was cleaved with TEV
protease and further puriﬁed by size exclusion chromatography using a
S200 HiLoad 16/60 Superdex column. A ﬁnal clean up step was
performed by reverse puriﬁcation on a Ni-sepharose column and the
puriﬁed protein stored at −80 °C.
X-ray Crystallography. Protein was concentrated to 10 mg/mL
buﬀered in 50 mM HEPES, pH 7.5, 300 mM NaCl, 10 mM DTT, 50
mM L-arginine, and 50 mM L-glutamate. Crystallization was performed
using the sitting drop vapor diﬀusion method at 4 °C. Viable crystals
of ALK2 in complex with 26 grew in a 150 nL drop, mixing the
protein, preincubated with 1 mM compound, with a reservoir solution
containing 0.2 M ammonium citrate and 20% PEG 3350 at 2:1 volume
ratio. Crystals were transferred into a cryoprotective solution prepared
from the mother liquor supplemented with 25% ethylene glycol.
Diﬀraction data were collected at Diamond Light Source, beamline
I04-I, and were processed and scaled with MOSFLM and AIMLESS
from the CCP4 suite.45 The crystals formed in space group I121 and
contained four protein molecules in the asymmetric unit. The
structure was solved by molecular replacement using PHASER46 and
the structure of the ALK2-LDN-193189 complex (PDB 3Q4U) as a
search model. Subsequent manual model building was performed
using COOT47 alternated with reﬁnement in REFMAC.48 TLS-
restrained reﬁnement was applied in the latter cycles using the input
thermal motion parameters determined by the TLSMD server.49 The
ﬁnal model was veriﬁed for geometry correctness with PHENIX
validation tools and MOLPROBITY.50,51 Data collection and
reﬁnement statistics are summarized in Supporting Information,
Table 5.
Kinase Assay. Puriﬁed recombinant ALK2 and ALK5 kinase
proteins (Invitrogen), ATP (Sigma), ATP [γ-32P] (PerkinElmer), and
dephosphorylated casein (Sigma) at ﬁnal concentrations of 2.5 nM, 6
μM, 0.05 μCi μL−1, and 0.5 mg mL−1, respectively, were aliquoted in
kinase buﬀer (Cell Signaling) containing 0.2% bovine serum albumin
supplemented with 10 mM MnCl2 into 96-microwell plates, in
combination with inhibitor compounds diluted at varying concen-
trations in kinase buﬀer (0.01 nM to 100 μM) in triplicate. In other
experiments, puriﬁed recombinant ALK2 mutant kinase proteins34
were incubated with γ-32P and substrate under similar conditions, but
in the presence of varying concentrations of unlabeled ATP, for the
determination of Km and Vmax for each ALK2 mutant. Positive control
samples lacking inhibitor compounds, and negative controls lacking
recombinant kinase, were also measured in triplicate. The mixture was
reacted at RT for 45 min, quenched with a ﬁnal concentration of 2%
phosphoric acid. The reaction mixture was transferred to 96-well P81
phosphocellulose ﬁlter plates (Millipore) and bound for 5 min. The
plates were washed 20 times with 150 μL of 1% phosphoric acid
solution per well by vacuum manifold. Plates were dried at RT for 1 h,
sealed, and assayed with Microscint 20 scintillation ﬂuid (PerkinElm-
er) using a Spectramax L luminometer (Molecular Devices) using the
photon counting setting with an integration time of one second per
well. Data was normalized to positive controls at 100% enzyme
activity, with negative controls being subtracted as background.
GraphPad (Prism software) was used for graphing and regression
analysis by sigmoidal dose−response with variable Hill coeﬃcient, or
by Michaelis−Menten analysis for the determination of Km.
Luciferase Reporter Assay. C2C12 myoﬁbroblasts cells stably
transfected with BMP responsive element from the Id1 promoter
fused to luciferase reporter gene (BRE-Luc) were generously provided
by Dr. Peter ten Dijke (Leiden University Medical Center, NL).52
Human embryonic kidney 293T cells stably transfected with the TGF-
β responsive element from the PAI-1 promoter fused to luciferase
reporter gene (CAGA-Luc) were generously provided by Dr. Howard
Weiner (Brigham and Women’s Hospital, Boston, MA).53 C2C12 Bre-
Luc and 293T CAGA-Luc cells were seeded in DMEM supplemented
with 2% FBS at 20000 cells per well in tissue culture treated 96-well
plates (Costar 3610; Corning). The cells were incubated for 1 h (37
°C and 10% CO2) and allowed to settle and attach. Compounds of
interest or DMSO were diluted in DMEM and added at ﬁnal
compound concentrations of 1 nM to 10 μM. Cells were then
incubated for 30 min. Adenovirus expressing constitutively active BMP
and TGF-β type I receptors (Ad.caALK1−5), generously provided by
Dr. Akiko Hata (University of California at San Francisco), were
added to achieve a multiplicity of infection (MOI) of 100. Plates were
incubated overnight at 37 °C. Cell viability was assayed with an 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) colori-
metric assay (Promega) per the manufacturer’s instructions. Media
was discarded, and ﬁreﬂy luciferase activity was measured (Promega)
according to manufacturer’s protocol. Light output was measured
using a Spectramax L luminometer (Molecular Devices) with an
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integration time of one second per well. Data was normalized to 100%
of incremental BRE-Luc activity due to adenoviruses specifying
caALK1, -2, or -3, or the incremental CAGA-Luc activity due to
adenoviruses specifying caALK4 or -5. Graphing and regression
analysis by sigmoidal dose−response with variable Hill coeﬃcient was
performed using GraphPad Prism software.
Cell Viability Assay. HepG2 hepatocarcinoma cells were seeded in
DMEM supplemented with 10% FBS at 25000 cells per well in tissue
culture treated 96-well plates (Costar 3610; Corning). The cells were
incubated for 2 h (37 °C and 5% CO2) and allowed to settle and
attach. Compounds of interest or DMSO were diluted in DMEM and
added at ﬁnal compound concentrations of 1, 10, and 100 μM. Cells
were incubated for 4 and 24 h, after which the media was discarded.
Cells were lysed by adding 30 μL of passive lysis buﬀer (Promega) and
shaken at RT for 15 min. Cell viability was determined by quantifying
the ATP present in each well by adding 10 μL of Cell Titer Glo
(Promega) per well and measuring the light output Spectramax L
luminometer (Molecular Devices) with an integration time of one
second per well. Data was normalized to 100% viability for cells
receiving only DMSO without any concurrent compound.
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